Study protocol: E-freeze - freezing of embryos in assisted conception: a randomised controlled trial evaluating the clinical and cost effectiveness of a policy of freezing embryos followed by thawed frozen embryo transfer compared with a policy of fresh embryo transfer, in women undergoing in vitro fertilisation.


Journal

Reproductive health
ISSN: 1742-4755
Titre abrégé: Reprod Health
Pays: England
ID NLM: 101224380

Informations de publication

Date de publication:
13 Jun 2019
Historique:
received: 26 04 2019
accepted: 13 05 2019
entrez: 15 6 2019
pubmed: 15 6 2019
medline: 19 12 2019
Statut: epublish

Résumé

Infertility affects one in seven couples; many of these need in vitro fertilisation (IVF). IVF involves external hormones to stimulate a woman's ovaries to produce eggs which are harvested surgically. Embryos, created in the laboratory by mixing eggs with sperm, are grown in culture for a few days before being replaced within the uterus (fresh embryo transfer). Spare embryos are usually frozen with a view to transfer at a later point in time - especially if the initial fresh transfer does not result in a pregnancy. Despite improvements in technology, IVF success rates remain low with an overall live birth rate of 25-30% per treatment. Additionally, there are concerns about health outcomes for mothers and babies conceived through IVF, particularly after fresh embryo transfer, including maternal ovarian hyperstimulation syndrome (OHSS) and preterm delivery. It is believed that high levels of hormones during ovarian stimulation could create a relatively hostile environment for embryo implantation whilst increasing the risk of OHSS. It has been suggested that freezing all embryos with the intention of thawing and replacing them within the uterus at a later stage (thawed frozen embryo transfer) instead of fresh embryo transfer, may lead to improved pregnancy rates and fewer complications. We aim to compare the clinical and cost effectiveness of fresh and thawed frozen embryo transfer, with the primary aim of identifying any difference in the chance of having a healthy baby. E-Freeze is a pragmatic, multicentre two-arm parallel group randomised controlled trial where women aged ≥18 and < 42 years, with at least three good quality embryos are randomly allocated to receive either a fresh or thawed frozen embryo transfer. The primary outcome is a healthy baby, defined as a term, singleton, live birth with appropriate weight for gestation. Cost effectiveness will be calculated from a healthcare and societal perspective. E-Freeze will determine the relative benefits of fresh and thawed frozen embryo transfer in terms of improving the chance of having a healthy baby. The results of this pragmatic study have the potential to be directly transferred to clinical practice. ISRCTN registry: ISRCTN61225414 . Date assigned 29/12/2015.

Sections du résumé

BACKGROUND BACKGROUND
Infertility affects one in seven couples; many of these need in vitro fertilisation (IVF). IVF involves external hormones to stimulate a woman's ovaries to produce eggs which are harvested surgically. Embryos, created in the laboratory by mixing eggs with sperm, are grown in culture for a few days before being replaced within the uterus (fresh embryo transfer). Spare embryos are usually frozen with a view to transfer at a later point in time - especially if the initial fresh transfer does not result in a pregnancy. Despite improvements in technology, IVF success rates remain low with an overall live birth rate of 25-30% per treatment. Additionally, there are concerns about health outcomes for mothers and babies conceived through IVF, particularly after fresh embryo transfer, including maternal ovarian hyperstimulation syndrome (OHSS) and preterm delivery. It is believed that high levels of hormones during ovarian stimulation could create a relatively hostile environment for embryo implantation whilst increasing the risk of OHSS. It has been suggested that freezing all embryos with the intention of thawing and replacing them within the uterus at a later stage (thawed frozen embryo transfer) instead of fresh embryo transfer, may lead to improved pregnancy rates and fewer complications. We aim to compare the clinical and cost effectiveness of fresh and thawed frozen embryo transfer, with the primary aim of identifying any difference in the chance of having a healthy baby.
METHODS METHODS
E-Freeze is a pragmatic, multicentre two-arm parallel group randomised controlled trial where women aged ≥18 and < 42 years, with at least three good quality embryos are randomly allocated to receive either a fresh or thawed frozen embryo transfer. The primary outcome is a healthy baby, defined as a term, singleton, live birth with appropriate weight for gestation. Cost effectiveness will be calculated from a healthcare and societal perspective.
DISCUSSION CONCLUSIONS
E-Freeze will determine the relative benefits of fresh and thawed frozen embryo transfer in terms of improving the chance of having a healthy baby. The results of this pragmatic study have the potential to be directly transferred to clinical practice.
TRIAL REGISTRATION BACKGROUND
ISRCTN registry: ISRCTN61225414 . Date assigned 29/12/2015.

Identifiants

pubmed: 31196113
doi: 10.1186/s12978-019-0737-2
pii: 10.1186/s12978-019-0737-2
pmc: PMC6567605
doi:

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Subventions

Organisme : Chief Scientist Office
ID : HERU1
Pays : United Kingdom
Organisme : Department of Health
ID : HTA/13/115/82
Pays : United Kingdom
Organisme : NIHR HTA
ID : 13/115/82

Références

Fertil Steril. 2011 Aug;96(2):344-8
pubmed: 21737072
Hum Reprod Update. 2012 Sep-Oct;18(5):485-503
pubmed: 22611174
BJOG. 2011 Aug;118(9):1073-83
pubmed: 21477172
Fertil Steril. 2013 Jan;99(1):156-162
pubmed: 23040524
J Assist Reprod Genet. 2010 Jul;27(7):357-63
pubmed: 20373015
Fertil Steril. 2011 Aug;96(2):516-8
pubmed: 21737071
Hum Fertil (Camb). 2008 Sep;11(3):131-46
pubmed: 18766953

Auteurs

Abha Maheshwari (A)

University of Aberdeen, Aberdeen, UK. abha.maheshwari@abdn.ac.uk.

Siladitya Bhattacharya (S)

University of Cardiff, Cardiff, UK.

Ursula Bowler (U)

University of Oxford, Oxford, UK.

Daniel Brison (D)

St. Mary's Hospital, Manchester, UK.

Tim Child (T)

University of Oxford, Oxford, UK.

Christina Cole (C)

University of Oxford, Oxford, UK.

Arri Coomarasamy (A)

Birmingham Women's Hospital, Birmingham, UK.

Rachel Cutting (R)

Jessop Wing Maternity Unit, Sheffield, UK.

Stephen Harbottle (S)

IVF Cambridge, Cambridge, UK.

Pollyanna Hardy (P)

University of Birmingham, Birmingham, UK.

Edmund Juszczak (E)

University of Oxford, Oxford, UK.

Yacoub Khalaf (Y)

Guy's and St. Thomas' Hospital, London, UK.

Jennifer J Kurinczuk (JJ)

University of Oxford, Oxford, UK.

Stuart Lavery (S)

IVF Hammersmith, London, UK.

Clare Lewis-Jones (C)

Formerly Fertility Network, London, UK.

Nick Macklon (N)

London Women's Clinic Group, London, UK.

Nick J Raine-Fenning (NJ)

University of Nottingham, Nottingham, UK.

Madhurima Rajkohwa (M)

Care Fertility, Birmingham, UK.

Graham Scotland (G)

University of Aberdeen, Aberdeen, UK.

Stephen Troup (S)

Reproductive Health, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH